Bibliography | 1.Salazar-González RA, Doll MA, Hein DW. Arylamine N-Acetyltransferase 1 Activity is Regulated by the Protein Acetylation Status. Front Pharmacol. 2022 Jan 27;13:797469. doi: 10.3389/fphar.2022.797469. PMID: 35153780; PMCID: PMC8828969. 2.Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells.Tiang JM, Butcher NJ, Minchin RF.
Biochem Biophys Res Commun. 2010 Feb 26; 393(1):95-100. 3.RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition.
Tiang JM, Butcher NJ, Cullinane C, Humbert PO, Minchin RF.PLoS One. 2011 Feb 9; 6(2):e17031. 4.Retrospective analysis of estrogen receptor 1 and N‑acetyltransferase gene expression in normal breast tissue, primary breast tumors, and established breast cancer cell lines.Carlisle SM, Hein DW.Int J Oncol. 2018 Aug; 53(2):694-702. 5.High N-Acetyltransferase 1 Expression Is Associated with Estrogen Receptor Expression in Breast Tumors, but Is not Under Direct Regulation by Estradiol, 5α-androstane-3β,17β-Diol, or Dihydrotestosterone in Breast Cancer Cells.Zhang X, Carlisle SM, Doll MA, Martin RCG, States JC, Klinge CM, Hein DW.J Pharmacol Exp Ther. 2018 Apr; 365(1):84-93. |